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Following publication of the original article \[[@CR1]\], the authors notified us of a typographical error in Table [1](#Tab1){ref-type="table"}.Table 1Patient Baseline Characteristics. The baseline demographics and clinical characteristics of patients with advanced EGFRm + NSCLC treated with first-line afatinib (*n* = 125) in our cohortCharacteristicNo.%Sex Male6451.2 Female6148.8Age at diagnosis, years Median62 Range26--86Ethnicity Chinese10080.0 Malay1411.2 Indian32.4 Others86.4Smoking status Never9576.0 Former1713.6 Current1310.4Histotype -- NSCLC Adenocarcinoma12196.8 Adenosquamous carcinoma10.8 NOS32.4EGFR mutation type Exon 19 deletion^\[a\]^8769.6 Exon 21 L858R2721.6 Others^\[b\]^118.8Brain metastases at baseline No8265.6 Yes4233.6 Unknown10.8Starting dose of afatinib once daily (OD) 40 mg6249.6 30 mg6148.8 20 mg10.8 Unknown10.8^a^E746_A750del; E746_A750delinsIP; E746_A750delinsQP; E746_A750delinsVP; E746_T751delinsV; E746_S752delinsV; E746_P753delinsVS; L747_A750delinsP; L747_T751del; L747_P753delinsS; NOS^b^E697Q; A763_Y764insFQEA; Double mutation; Unknown NSCLC Non-small cell lung cancer, NOS Not otherwise specified

The corrected Table [1](#Tab1){ref-type="table"} is presented below.
